Shoulder Innovations, Inc. ((SI)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shoulder Innovations, Inc. struck an upbeat tone on its latest earnings call, highlighting strong revenue growth, rising procedure volumes and expanding surgeon adoption. Management emphasized improving gross margins and rapid progress across its product and technology pipeline, while acknowledging wider losses and heavier cash use as it invests to scale, and maintained clear confidence by raising full‑year guidance.
Strong Top-Line Growth
Net revenue reached $16.7 million in the first quarter of 2026, a 65% jump from a year earlier and 16% higher than the prior quarter. Management credited the surge to new surgeon adoption, greater utilization among existing users and higher average selling prices, signaling that both volume and pricing are contributing to the top line.
Raised Full-Year Guidance
The company lifted its 2026 revenue outlook to a range of $65 million to $68 million, implying 37% to 44% growth versus 2025. This compares with a prior guide of $62 million to $65 million, and underscores management’s conviction that current momentum in procedures and account wins can be sustained through the year.
High and Improving Gross Margins
Gross margin improved to 77.7% in the quarter, up from 76.9% a year earlier, reflecting favorable mix and operational efficiencies. Executives expect margins to remain at similar levels for the rest of 2026, with additional upside over time as cost‑down programs and scaling benefits take hold.
Surgeon Adoption and Volume Gains
Total implant volume climbed to 2,184 units in the quarter, up 51% year over year, highlighting strong clinical uptake. The core and contender surgeon base stood at 134 at the end of 2025, up 61%, and the company more than doubled new customers entering its funnel versus the same period last year.
Commercial and Educational Momentum
Shoulder Innovations ran 44 company‑sponsored educational events in the quarter, using training and symposia as a key growth lever. Attendance at its 2026 Napa symposium rose more than 70%, and over 70% of non‑customer attendees have already performed or committed to their first or increased cases, pointing to a robust near‑term conversion pipeline.
Product and Technology Milestones
The I‑135RFX humeral stem moved from limited release to full commercial launch, with expanded indications for fracture cases, broadening the addressable market. The company also began a limited release of its N22 Glenosphere, passed 500 patients in its clinical registry and reported that its micro‑robotic partnership is progressing ahead of expectations.
Cash Position and Fulfillment Strategy
Cash and cash equivalents totaled $108.5 million at the end of March 2026, giving the company a sizable liquidity cushion. Management has deliberately increased inventory and asset purchases to support accelerated growth and avoid supply bottlenecks, and expects materially lower cash burn beginning in the second quarter.
Widening Operating Losses
Despite strong revenue growth, the company’s net loss widened to $8.4 million in the quarter from $4.7 million a year earlier. Adjusted EBITDA loss also expanded to $7.0 million from $3.5 million, reflecting heavier spending to build out commercial infrastructure and advance the product pipeline.
Higher SG&A and R&D Investment
Selling, general and administrative expense rose to $18.2 million from $10.5 million, driven by expanded sales headcount and higher variable selling costs tied to growth. Research and development spending climbed to $3.8 million from $1.6 million, as the company invests in new implants and its emerging robotic platform.
Q1 Cash Burn and Working Capital
Management acknowledged that cash burn was elevated in the first quarter, largely due to proactive inventory builds, capital purchases and working capital swings. While this weighed on near‑term liquidity trends, the company framed these moves as necessary to stay ahead of demand and reiterated expectations for significantly lower burn starting in the second quarter.
Seasonality and ASP/Mix Variability
The updated outlook bakes in typical seasonality, with a softer third quarter and a step‑up in the fourth quarter as procedure volumes rebound. Average selling prices benefited the first quarter, but leadership cautioned that ASPs may fluctuate from quarter to quarter given changes in product mix and case or payer mix.
Contender Category Dynamics
Growth in the “contender” surgeon category moderated in the quarter, as more of these physicians transitioned into the higher‑volume core segment by design. Management noted that this migration is positive for long‑term revenue durability, though it can temporarily distort growth patterns as the customer base matures.
Forward-Looking Guidance and Outlook
Looking ahead, the company expects 2026 revenue between $65 million and $68 million, supported by stable high‑70s gross margins and continued volume growth. Guidance assumes some seasonal softness and ASP variability, modestly higher SG&A as a percentage of revenue in the middle quarters to fund expansion, and lower R&D intensity later in the year, with leadership confident that current cash resources can carry it toward cash‑flow breakeven.
Shoulder Innovations’ latest call painted a picture of a fast‑growing business using its balance sheet to secure future scale, even at the cost of near‑term losses. For investors, the key watchpoints will be whether surgeon adoption and procedure volumes continue to compound, whether gross margins hold near current levels and how quickly operating leverage emerges as spending moderates.